# Ocrevus (ocrelizumab)

Type: Product (RHHBY)

Source: GetYourBrief — https://getyourbrief.com/entity/ocrevus-ocrelizumab
Canonical HTML page: https://getyourbrief.com/entity/ocrevus-ocrelizumab

## Recent coverage (2 stories, network-wide)

### MS Patients Face $33K/Year Without PBS as Review Eyes 50% Price Cut
2026-07-15 21:43:35 · Sector: health · Sentiment: Negative · Impact: 7/10 · Sources: 11

Two of Australia’s most used MS therapies, Ocrevus and Kesimpta, face a PBS pricing review that could slash subsidies by 40–50%. Without coverage, patients could pay over $33,000 annually, jeopardizing treatment access for thousands.
Full story: https://gethealthbrief.com/story/pbs-ms-treatments-review-health

### Novartis, Roche Face 50% PBS Price Cut on MS Drugs as Briumvi Triggers Review
2026-07-15 21:43:22 · Sector: bio · Sentiment: Negative · Impact: 7/10 · Sources: 11

A July 2026 Australian PBS review for Roche's Ocrevus and Novartis’s Kesimpta could reduce government reimbursement by up to 50%, triggered by reference pricing with new low-cost entrant Briumvi. Manufacturers risk margin erosion or market withdrawal.
Full story: https://getbiobrief.com/story/pbs-ms-review-pharma

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.